Delivery Order SPE2DB22D3301-SPE2DB25FY9PT
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,846.97 on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vyndamax 61 mg capsules (unit dose, 30-count packages) with a ceiling value of $55,387.88. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This firm fixed-price delivery order, valued at $13,846.97, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This competitively awarded, non-set-aside contract carries a ceiling value of $13,846.97 and employs firm fixed pricing. The delivery order is set for ultimate completion by September 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Vyndamax 61 mg capsule unit dose packs (30-count) with a ceiling value of $13,846.97. This firm fixed-price delivery order, which must be completed by May 15, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.9 billion through December 2026. The award was not set-aside and was...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). The contract, which is not set-aside and carries a firm fixed price structure, is scheduled for ultimate completion by July 14, 2025. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $13,846.97 on April 24, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). The contract, which is not set-aside, carries a completion date of May 15, 2025, and operates under a firm fixed-price delivery order structure. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packages of 30 count. This is a firm fixed price delivery order with a ceiling value of $27,693.94 and an ultimate completion date of September 16, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a firm fixed price structure. The contract, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY9PTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Vyndamax 61 mg capsule unit dose in quantities of 30, with a firm fixed price ceiling value of $41,540.91 and an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract represents a direct purchase under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical supply vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's broader role as a major pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. As a critical vendor within the Defense Health Agency's supply chain, the company maintains an extensive portfolio of pharmaceutical products and medical supplies across multiple therapeutic domains. The current award for Vyndamax, a medication used in the treatment of transthyretin amyloidosis, exemplifies the company's capability to supply specialized pharmaceuticals through the DLA's competitive procurement process.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $41.5k | 8/19/25 |